Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Health Administration Center, Shiga University of Medical Science, Otsu, Shiga, Japan.
Am J Respir Cell Mol Biol. 2020 Jul;63(1):67-78. doi: 10.1165/rcmb.2019-0377OC.
Epithelial dysfunction in the small airways may cause the development of emphysema in chronic obstructive pulmonary disease. C/EBPα (CCAAT/enhancer binding protein-α), a transcription factor, is required for lung maturation during development, and is also important for lung homeostasis after birth, including the maintenance of serine protease/antiprotease balance in the bronchiolar epithelium. This study aimed to show the roles of C/EBPα in the distal airway during chronic cigarette smoke exposure in mice and in the small airways in smokers. In a model of chronic smoke exposure using epithelial cell-specific C/EBPα-knockout mice, significant pathological phenotypes, such as higher protease activity, impaired ciliated cell regeneration, epithelial cell barrier dysfunction via reduced zonula occludens-1 (Zo-1), and decreased alveolar attachments, were found in C/EBPα-knockout mice compared with control mice. We found that (serine protease inhibitor kazal-type 5) gene (encoding lymphoepithelial Kazal-type-related inhibitor [LEKTI], an anti-serine protease) expression in the small airways is a key regulator of protease activity in this model. Finally, we showed that daily antiprotease treatment counteracted the phenotypes of C/EBPα-knockout mice. In human studies, (CCAAT/enhancer binding protein-α) gene expression in the lung was downregulated in patients with emphysema, and six smokers with centrilobular emphysema (CLE) showed a significant reduction in LEKTI in the small airways compared with 22 smokers without CLE. LEKTI downregulation in the small airways was associated with disease development during murine small airway injury and CLE in humans, suggesting that LEKTI might be a key factor linking small airway injury to the development of emphysema.
小气道上皮功能障碍可能导致慢性阻塞性肺疾病发生肺气肿。CCAAT/增强子结合蛋白α(C/EBPα)是一种转录因子,它是肺在发育过程中成熟所必需的,并且在出生后对肺稳态也很重要,包括在细支气管上皮中维持丝氨酸蛋白酶/抗蛋白酶平衡。本研究旨在展示 C/EBPα 在慢性香烟烟雾暴露的小鼠远端气道和吸烟者的小气道中的作用。在使用上皮细胞特异性 C/EBPα 敲除小鼠的慢性烟雾暴露模型中,与对照组小鼠相比,C/EBPα 敲除小鼠表现出明显的病理表型,如更高的蛋白酶活性、纤毛细胞再生受损、上皮细胞屏障功能障碍(通过减少闭合蛋白-1 [Zo-1])和肺泡附着减少。我们发现,小气道中 (丝氨酸蛋白酶抑制剂 kazal 型 5)基因(编码淋巴上皮 kazal 型相关抑制剂 [LEKTI],一种抗丝氨酸蛋白酶)的表达是该模型中蛋白酶活性的关键调节因子。最后,我们表明,每天使用抗蛋白酶治疗可逆转 C/EBPα 敲除小鼠的表型。在人类研究中,肺气肿患者的肺中 (CCAAT/增强子结合蛋白-α)基因表达下调,22 名无中央小叶肺气肿(CLE)的吸烟者的小气道中 LEKTI 明显减少,而 6 名有 CLE 的吸烟者则明显减少。LEKTI 在小气道中的下调与小鼠小气道损伤和人类 CLE 期间的疾病发展有关,这表明 LEKTI 可能是将小气道损伤与肺气肿发展联系起来的关键因素。